Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Prozac Nation, Street Version

      Headlines

      Fri, 25 Jul 2014

      physician education sessions, expanded 49%. During the conference call, management mentioned that contracts with Novartis NVS and King Pharmaceuticals KG have started contributing to this segment. Revenues from the prepackaged medications segment

    2. FDA accepts BLA for biosimilar of Amgen's Neupogen

      Headlines

      Thu, 24 Jul 2014

      The FDA accepts the Biologics License Application (BLA) for filgrastim filed by Novartis ' ( NVS +0.3% ) Sandoz. The reference product is Amgen's ( AMGN +0.1% ) Neupogen . Sandoz markets the product under the brand

    3. New Morningstar Analyst Report for GlaxoSmithKline PLC

      Stock Reports

      Thu, 24 Jul 2014

      2014 restructuring of divisions with Novartis should bode well for Glaxo. In the ..... completion of the restructuring with Novartis (2015), we forecast average annual ..... completion of the restructuring with Novartis (2015), we forecast average annual

    4. XLV Health Care Select Sector SPDR® ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      criteria eliminate foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi SNY. That said, we'd note that most of the firms included here are large

    5. IYH iShares US Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      fund does not own companies that are domiciled overseas. As a result, international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi SNY are nowhere to be found. That said, many of the firms in this ETF have

    6. VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      owns only companies domiciled in the United States, which means that it doesn't invest in foreign behemoths such as Novartis NVS , Roche, and Sanofi SNY. That said, many of the companies in VHT operate businesses spanning the globe, which ensures

    7. U.S. paves way for Novartis to copy Amgen biotech drug

      Headlines

      Thu, 24 Jul 2014

      July 24 (Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for...

    8. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Wed, 23 Jul 2014

      is losing its edge as the leading MS drug, as similar competitors nip at its heels and novel oral therapies, such as Novartis ' Gilenya and Sanofi's Aubagio, enter the market.Tysabri's efficacy could be overshadowed by worrisome side effects

    9. Glaxo Posts Weak 2Q as Pricing Pressures Continue to Weigh on Top Drug Advair

      Commentary

      Wed, 23 Jul 2014

      t expect any changes to Glaxo's wide moat rating. Further, the structural changes previously announced (adding Novartis ' vaccine and consumer units while selling oncology assets) should better position Glaxo in therapeutic areas where the

    10. Update: Google Teaming Up With Novartis To Develop Smart Lenses

      Headlines

      Fri, 18 Jul 2014

      By BB Research : Novartis (NYSE: NVS ) just announced that it is teaming ..... various intraocular conditions. Novartis ' eye care division Alcon has entered ..... the deal hasn't been disclosed, Novartis said that Google's technology will

    « Prev12345Next »
    Content Partners